AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29696238 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender- and culturally-sensitive weight loss intervention (GCSWLI) for 24 weeks, including a 12-week in-person phase with weekly sessions and a 12-week follow-up with bi-weekly phone calls.
Number of subjects: 50
Study 29696238 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC) group received no intervention during the initial 24 weeks but later received the GCSWLI plus mobile health technology support.
Number of subjects: 50
Study 29696581 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass (CPB)
Number of subjects: 64
Study 29696581 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 64
Study 29698249 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater number of invasive procedures
Number of subjects: 36
Study 29698249 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater anxiety recalled about infant's invasive procedures
Number of subjects: 36
Study 29699410 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 0
Study 29699477 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial translocation positive (bactDNA(+)) patients
Number of subjects: 30
Study 29699477 — intervention group
Group type: COMPARATOR
Intervention: Bacterial translocation negative (bactDNA(-)) patients
Number of subjects: 30
Study 29699477 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (bactDNA(+) and bactDNA(-))
Number of subjects: 30
Study 29699493 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to current antimicrobial guidelines (2016 Chinese CAP guidelines)
Number of subjects: 3131
Study 29699493 — intervention group
Group type: COMPARATOR
Intervention: Non-adherent treatment (62.1% of patients)
Number of subjects: 3131
Study 29699493 — intervention group
Group type: COMPARATOR
Intervention: Over-treatment in general-ward patients (52.3% over-treated)
Number of subjects: 3131
Study 29699493 — intervention group
Group type: COMPARATOR
Intervention: Under-treatment in ICU patients (71.4% under-treated)
Number of subjects: 3131
Study 29699493 — intervention group
Group type: COMPARATOR
Intervention: Under-treatment in general-ward patients with risk factors for PA infection (22.9% under-treated)
Number of subjects: 3131
Study 29699493 — intervention group
Group type: COMPARATOR
Intervention: Under-treatment in ICU patients with risk factors for PA infection (74.2% under-treated)
Number of subjects: 3131
Study 29699498 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic response (E+)
Number of subjects: 202
Study 29699498 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker response (B+)
Number of subjects: 202
Study 29699498 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical response (C+)
Number of subjects: 202
Study 29699498 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic responders (E+)
Number of subjects: 202
Study 29699498 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical responders (C+)
Number of subjects: 202
Study 29699498 — intervention group
Group type: COMPARATOR
Intervention: Non-responders (E-/C-)
Number of subjects: 202
Study 29699498 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker response
Number of subjects: 202
Study 29699498 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical response
Number of subjects: 202
Study 29699498 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite score of response measures
Number of subjects: 202
Study 29699614 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS) implantation
Number of subjects: 20
Study 29699913 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor environmental pollutants (EPS)
Number of subjects: 718
Study 29699913 — intervention group
Group type: COMPARATOR
Intervention: Outdoor air pollutants
Number of subjects: 718
Study 29699961 — intervention group
Group type: EXPERIMENTAL
Intervention: Social networking-based intervention (Facebook)
Number of subjects: 24
Study 29700101 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid (DA) in combination with a brief Q&A session with a genetic counsellor
Number of subjects: 0
Study 29700101 — intervention group
Group type: COMPARATOR
Intervention: Genetic counselling alone
Number of subjects: 0
Study 29700172 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-transplant infusion of cyclophosphamide
Number of subjects: 0
Study 29700872 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab-supplemented Oral Immunotherapy (OIT)
Number of subjects: 13
Study 29701105 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 299
Study 29701107 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive naturopathic oncology (NO) specialty care
Number of subjects: 2
Study 29701107 — intervention group
Group type: COMPARATOR
Intervention: Standard oncologic care
Number of subjects: 2
Study 29701939 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral rTMS
Number of subjects: 156
Study 29701939 — intervention group
Group type: EXPERIMENTAL
Intervention: Left unilateral rTMS
Number of subjects: 156
Study 29701939 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 156
Study 29701939 — intervention group
Group type: COMPARATOR
Intervention: Bilateral rTMS vs Sham rTMS
Number of subjects: 156
Study 29701939 — intervention group
Group type: COMPARATOR
Intervention: Left unilateral rTMS vs Sham rTMS
Number of subjects: 156
Study 29701939 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in suicidal ideation
Number of subjects: 156
Study 29701939 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in HDRS-16 score
Number of subjects: 156
Study 29702001 — intervention group
Group type: COMPARATOR
Intervention: MC1.0
Number of subjects: 131
Study 29702001 — intervention group
Group type: COMPARATOR
Intervention: CMC
Number of subjects: 131
Study 29702295 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS-FD (patients with functional dyspepsia)
Number of subjects: 205
Study 29702295 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS (patients without functional dyspepsia)
Number of subjects: 205
Study 29702295 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 205
Study 29702295 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety levels
Number of subjects: 205
Study 29702295 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatization severity
Number of subjects: 205
Study 29702295 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaled hydrogen levels
Number of subjects: 205
Study 29703168 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-based media consumption (TV/video, game console, PC/internet, mobile phone)
Number of subjects: 850
Study 29703168 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower consumption of computers/internet
Number of subjects: 850
Study 29703168 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower consumption of TV/video and higher frequency of non-organized physical activity
Number of subjects: 850
Study 29703168 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-organized physical activity
Number of subjects: 850
Study 29703168 — intervention group
Group type: EXPERIMENTAL
Intervention: Media consumption
Number of subjects: 850
Study 29703168 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 850
Study 29703211 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 502
Study 29703211 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower level of education
Number of subjects: 502
Study 29703211 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure
Number of subjects: 502
Study 29703211 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 502
Study 29703211 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 502
Study 29703211 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher blood pressure
Number of subjects: 502
Study 29703211 — intervention group
Group type: EXPERIMENTAL
Intervention: Living alone
Number of subjects: 502
Study 29703211 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher diastolic blood pressure
Number of subjects: 502
Study 29703211 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 502
Study 29703211 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher body mass index
Number of subjects: 502
Study 29703235 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis ssp. lactis B94
Number of subjects: 36
Study 29703235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 29703237 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Wise intervention (various components including peer or licensed facilitator, group dialogue, personal goal development, community organizing, and a core critical-thinking component)
Number of subjects: 528
Study 29703237 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (not specified in detail)
Number of subjects: 528
Study 29703712 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied growth factors combined with protease inhibitor wound dressings
Number of subjects: 0
Study 29703712 — intervention group
Group type: COMPARATOR
Intervention: Topically applied growth factors with standard wound dressings
Number of subjects: 0
Study 29703778 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) plus bendamustine
Number of subjects: 55
Study 29703852 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Warning Scores (EWS)
Number of subjects: 16386
Study 29703852 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological parameters
Number of subjects: 16386
Study 29703851 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT) from an anonymous healthy donor
Number of subjects: 80
Study 29703851 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 80
Study 29703851 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups continue weekly self-administered subcutaneous MTX treatment (15-25 mg/week)
Number of subjects: 80
Study 29705220 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg
Number of subjects: 278
Study 29705219 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometry assessment of CD64 levels
Number of subjects: 781
Study 29705219 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometry assessment of circulating IGs
Number of subjects: 781
Study 29705265 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-0976 20 mg orally once daily for 12 weeks
Number of subjects: 10
Study 29705265 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-0976
Number of subjects: 10
Study 29705265 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (controls), n = 10
Number of subjects: 10
Study 29705265 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with NASH
Number of subjects: 10
Study 29705733 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal oestrogen ring used continuously for 8 years
Number of subjects: 1
Study 29705733 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (cruciate incision in the cervicovaginal scar)
Number of subjects: 1
Study 29705733 — intervention group
Group type: COMPARATOR
Intervention: Topical immunosuppression for GVHD
Number of subjects: 1
Study 29705753 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 0
Study 29705753 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity continuous training (CT)
Number of subjects: 0
Study 29705753 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT combined with fasting
Number of subjects: 0
Study 29705753 — intervention group
Group type: COMPARATOR
Intervention: CT combined with fasting
Number of subjects: 0
Study 29705765 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation
Number of subjects: 0
Study 29706375 — intervention group
Group type: EXPERIMENTAL
Intervention: Balixafortide plus eribulin
Number of subjects: 56
Study 29706375 — intervention group
Group type: COMPARATOR
Intervention: Eribulin
Number of subjects: 56
Study 29706375 — intervention group
Group type: COMPARATOR
Intervention: Balixafortide
Number of subjects: 56
Study 29706508 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid CTO PCI
Number of subjects: 3055
Study 29706508 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade wire escalation
Number of subjects: 3055
Study 29706508 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde strategy
Number of subjects: 3055
Study 29706508 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade dissection re-entry
Number of subjects: 3055
Study 29706508 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple crossing strategies
Number of subjects: 3055
Study 29706508 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast volume
Number of subjects: 3055
Study 29706508 — intervention group
Group type: EXPERIMENTAL
Intervention: Air kerma radiation dose
Number of subjects: 3055
Study 29706508 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure time
Number of subjects: 3055
Study 29706508 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy time
Number of subjects: 3055
Study 29706550 — intervention group
Group type: EXPERIMENTAL
Intervention: Aging (comparison between younger and older adults)
Number of subjects: 0
Study 29706550 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin cohort analysis
Number of subjects: 0
Study 29706993 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing on a moving platform
Number of subjects: 0
Study 29706993 — intervention group
Group type: COMPARATOR
Intervention: Traditional balance exercises
Number of subjects: 0
Study 29706998 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg/day)
Number of subjects: 17
Study 29707200 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin administration
Number of subjects: 0
Study 29707200 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29707231 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific training programme (four specific exercises, three difficulty levels intensified every second week, completed four times a week for 10 minutes per session over 14 weeks)
Number of subjects: 72
Study 29707231 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific training programme
Number of subjects: 72
Study 29707528 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrective surgery
Number of subjects: 21
Study 29707528 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative surgery
Number of subjects: 21
Study 29707537 — intervention group
Group type: EXPERIMENTAL
Intervention: Inertial Measurement Unit sensors during daily life
Number of subjects: 4
Study 29707537 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily-life recorded kinematics
Number of subjects: 4
Study 29707537 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily-life activities
Number of subjects: 4
Study 29707537 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical assessments
Number of subjects: 4
Study 29707565 — intervention group
Group type: COMPARATOR
Intervention: Normal weight women (BMI < 25)
Number of subjects: 207
Study 29707565 — intervention group
Group type: COMPARATOR
Intervention: Overweight women (BMI 25-29.9)
Number of subjects: 207
Study 29707565 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese women (BMI ≥ 30)
Number of subjects: 207
Study 29708007 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to improve physical function and caregiver perceptions
Number of subjects: 0
Study 29708906 — intervention group
Group type: EXPERIMENTAL
Intervention: TempZHF (SpotOn sensor)
Number of subjects: 49
Study 29708906 — intervention group
Group type: COMPARATOR
Intervention: TempEso (oesophageal probe)
Number of subjects: 49
Study 29708906 — intervention group
Group type: COMPARATOR
Intervention: TempArt (thermodilution arterial catheter)
Number of subjects: 49
Study 29709062 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo-immunotherapy followed by radio-immunotherapy and 2 years of rituximab maintenance
Number of subjects: 33
Study 29709062 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio-immunotherapy
Number of subjects: 33
Study 29709062 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo-immunotherapy
Number of subjects: 33
Study 29709062 — intervention group
Group type: EXPERIMENTAL
Intervention: Post radio-immunotherapy
Number of subjects: 33
Study 29709062 — intervention group
Group type: EXPERIMENTAL
Intervention: Post treatment
Number of subjects: 33
Study 29709335 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management behavior
Number of subjects: 1055
Study 29709335 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to insulin therapy
Number of subjects: 1055
Study 29709335 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot care
Number of subjects: 1055
Study 29709335 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy eating
Number of subjects: 1055
Study 29709335 — intervention group
Group type: EXPERIMENTAL
Intervention: Interest in improving healthy eating and physical activity
Number of subjects: 1055
Study 29709335 — intervention group
Group type: EXPERIMENTAL
Intervention: Interest in improving self-management behaviors
Number of subjects: 1055
Study 29709335 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare provider communication about A1c
Number of subjects: 1055
Study 29710075 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg twice daily
Number of subjects: 90
Study 29710075 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 90
Study 29710075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 29710208 — intervention group
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy
Number of subjects: 42
Study 29710226 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufficient functional health literacy (FHL)
Number of subjects: 704
Study 29710226 — intervention group
Group type: EXPERIMENTAL
Intervention: Problematic functional health literacy (FHL)
Number of subjects: 704
Study 29710226 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate functional health literacy (FHL)
Number of subjects: 704
Study 29710226 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate FHL
Number of subjects: 704
Study 29710226 — intervention group
Group type: COMPARATOR
Intervention: Functional health literacy groups
Number of subjects: 704
Study 29710408 — intervention group
Group type: EXPERIMENTAL
Intervention: PreventADALL intervention
Number of subjects: 0
Study 29712625 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing-based substance use brief intervention (SUBI)
Number of subjects: 600
Study 29712625 — intervention group
Group type: COMPARATOR
Intervention: Standard HIV counseling, testing, and referral (CTR)
Number of subjects: 600
Study 29712625 — intervention group
Group type: EXPERIMENTAL
Intervention: CTR followed by SUBI
Number of subjects: 600
Study 29712625 — intervention group
Group type: EXPERIMENTAL
Intervention: SUBI followed by CTR
Number of subjects: 600
Study 29712627 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote collaborative care program (n=111)
Number of subjects: 250
Study 29712627 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=139)
Number of subjects: 250
Study 29712654 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Dose Oral LCB01-0371, a novel oxazolidinone
Number of subjects: 0
Study 29712654 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29713194 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 354
Study 29713194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study 29713483 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT)
Number of subjects: 693
Study 29713483 — intervention group
Group type: COMPARATOR
Intervention: ESC-SCORE
Number of subjects: 693
Study 29713493 — intervention group
Group type: EXPERIMENTAL
Intervention: EcN suspension orally for 3 weeks
Number of subjects: 62
Study 29713493 — intervention group
Group type: COMPARATOR
Intervention: Control group (observation only)
Number of subjects: 62
Study 29713493 — intervention group
Group type: EXPERIMENTAL
Intervention: EcN treatment
Number of subjects: 62
Study 29713498 — intervention group
Group type: EXPERIMENTAL
Intervention: ramucirumab+FOLFIRI
Number of subjects: 1057
Study 29713498 — intervention group
Group type: COMPARATOR
Intervention: placebo+FOLFIRI
Number of subjects: 1057
Study 29713498 — intervention group
Group type: EXPERIMENTAL
Intervention: bevacizumab+FOLFIRI
Number of subjects: 1057
Study 29713498 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI alone
Number of subjects: 1057
Study 29713524 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of Ranibizumab (IVR)
Number of subjects: 33
Study 29713524 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal injection of Bevacizumab (IVB)
Number of subjects: 33
Study 29713840 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal Achievement Training (GAT)
Number of subjects: 0
Study 29713930 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted transabdominal preperitoneal (R-TAPP) hernia repair
Number of subjects: 0
Study 29713930 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29713962 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Number of subjects: 0
Study 29713962 — intervention group
Group type: COMPARATOR
Intervention: Insulin Glargine U100
Number of subjects: 0
Study 29714167 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (RTG)
Number of subjects: 20
Study 29714167 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)
Number of subjects: 20
Study 29714167 — intervention group
Group type: COMPARATOR
Intervention: Control (TDF/FTC)
Number of subjects: 20
Study 29714603 — intervention group
Group type: EXPERIMENTAL
Intervention: GDF-15 centile values (age-dependent)
Number of subjects: 268
Study 29714603 — intervention group
Group type: EXPERIMENTAL
Intervention: GDF-15 centile values (≥95th vs <95th)
Number of subjects: 268
Study 29715056 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax 400 mg per day after an initial dose ramp up
Number of subjects: 158